Trials / Unknown
UnknownNCT02386007
Phase 2a Study to Evaluate Optimum Dosage and Stability of DW-3101 in Gastric Inflammation Patients
A Double-blind, Multicenter, Randomized Phase 2a Study to Evaluate Optimum Dosage and Stability of DW-3101 in Korean Patients With Gastric Inflammation
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Daewon Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find optimum dosage of DW-3101 by evaluating efficacy and safety of each dosage group in Korean patients with acute and chronic gastric inflammation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DW-3101_150mg | |
| DRUG | DW-3101_300mg | |
| DRUG | DW-3101_600mg | |
| DRUG | Placebo |
Timeline
- Primary completion
- 2017-07-01
- First posted
- 2015-03-11
- Last updated
- 2016-10-12
Source: ClinicalTrials.gov record NCT02386007. Inclusion in this directory is not an endorsement.